Clinical trials: CTIT-Chemotherapy Induced Thrombocytopenia
CTIT-Chemotherapy Induced Thrombocytopenia
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
- Trial name
- NCT06440824
- Testing
- Romiplostim N01, Recombinant Human Thrombopoietin
- Volunteers
- 60 people
- Sponsor
- Shandong University
CTIT-Chemotherapy Induced Thrombocytopenia
TPO Combined With TPORA for Solid Tumors Effectiveness of cTit Above Degree II
This study was an open-label, controlled, single-center, prospective phase II trial. In this prospective, real-world study, consecutive patients meeting eligibility criteria will be enrolled and allocated to: Group A (Grade Ⅱ…
- Trial name
- NCT06769685
- Testing
- rhTPO, hypertrombopa
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinhua Central Hospital
Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
This study is a prospective clinical study enrolling breast cancer patients at high risk of chemotherapy-induced thrombocytopenia (CTIT).
- Trial name
- PROTECT (NCT07647029)
- Testing
- Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles
- Volunteers
- 126 people
- Sponsor
- Fudan University
CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer
Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study
The title of this study is: A two-cohort, single-arm, exploratory Phase II clinical study on the primary/secondary prevention ADC drug of heltrombopag for thrombocytopenia caused by breast cancer.
- Trial name
- NCT07243418
- Testing
- herombopag olamine tablets
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia
A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma
This study is a single-arm, exploratory, self-controlled clinical trial for the prevention of thrombocytopenia induced by gemcitabine plus cisplatin in the treatment of nasopharyngeal carcinoma.
- Trial name
- NCT07252375
- Testing
- herombopag olamine tablets
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia
A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors
The purpose of this clinical trial is to evaluate the safety and efficacy of Romiplostim N01 in patients with solid tumors who are undergoing concurrent/sequential radiotherapy and chemotherapy（combined with/without…
- Conditions
- Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia
- Trial name
- NCT07185893
- Testing
- Human Interleukin-11, Romiplostim N01
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Jun wang